Ahmedabad (Gujarat) [India], August 11 (ANI/PNN): Dishman Carbogen Amcis Ltd, a fully integrated CRAMS (Contract Research and Manufacturing) company with strong capabilities right from process research and development to late-stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies, have announced their first quarter (Q1FY23) results. Financial performance Consolidated Q1FY23 review Consolidated Q1FY23 review - Net revenue was Rs 5,406mn for Q1 FY23 as compared to Rs 5,507mn in the corresponding period of the previous year - EBITDA stood at Rs 904 mn for Q1 FY23 as compared to Rs 1,006 mn during the corresponding period of previous year - EBITDA Margin at 16.7 per cent for Q1 FY23 as against 18.3 per cent in Q1 FY22 - Net Profit stood at Rs 40 mn for Q1 FY23 as compared to Rs 160 mn in the corresponding period of the previous year Q1 FY23Result Highlights - Net Revenue at Rs 5,406 mn in Q1 FY23 down by 1.8 per cent YoY mainly on account of low
Players In The HP (High Potency) APIs Market Focus On Expansion Strategies To Strengthen Their Positions einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
A financial services company is fighting a $1.3 million lawsuit brought by a Swiss drug developer, saying it did not have to pay profits made by the pharmaceutical company under currency exchange contracts because they were allegedly entered into for speculative purposes.
High Potency Active Pharmaceutical Ingredients Market revenue to cross USD 40,983.8 Million By 2027, pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.